Initial Treatment for Lupus Nephritis Class IV

First-Line Treatment Options

The American College of Rheumatology recommends mycophenolic acid (MPA) (mycophenolate mofetil [MMF] target dose: 2-3 g/day for 6 months) or low-dose intravenous cyclophosphamide (total dose 3 g over 3 months) in combination with glucocorticoids for patients with class IV lupus nephritis, as they have the best efficacy/toxicity ratio 1
The European League Against Rheumatism suggests that mycophenolic acid (MPA) sodium at equivalent dose can be used as an alternative to MMF 2
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend MPA for patients at high risk for infertility or with prior cyclophosphamide exposure 3

The American College of Rheumatology recommends initial treatment with three consecutive pulses of intravenous methylprednisolone (500-750 mg each), followed by oral prednisone 0.3-0.5 mg/kg/day for up to 4 weeks, and taper to ≤7.5 mg/day by 3-6 months 1, 2

The European League Against Rheumatism suggests that combination therapy with MMF (target dose: 1-2 g/day) plus a calcineurin inhibitor (especially tacrolimus) is an alternative, particularly effective for patients with nephrotic-range proteinuria 1, 4
The American College of Rheumatology recommends high-dose intravenous cyclophosphamide (0.5-0.75 g/m² monthly for 6 months) for patients at high risk for kidney failure, defined by reduced GFR, histological presence of crescents or fibrinoid necrosis, and severe interstitial inflammation 1

The American College of Rheumatology recommends co-administration of hydroxychloroquine (dose not to exceed 5 mg/kg/day and adjusted for GFR) 1
The European Society of Cardiology recommends angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for all patients with UPCR >500 mg/g or arterial hypertension 1
The American College of Cardiology recommends statins based on lipid levels and estimated 10-year cardiovascular disease risk 1

The American College of Rheumatology recommends treatment aims for preservation or improvement of kidney function with reduction in proteinuria of at least 25% by 3 months, 50% reduction by 6 months, and UPCR target below 500-700 mg/g by 12 months (complete clinical response) 1

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend continuing with MMF at lower doses (1-2 g/day) or switching to azathioprine (2 mg/kg/day) if pregnancy is contemplated, and maintaining low-dose prednisone (2.5-5 mg/day) when needed to control disease activity 1, 3

The American College of Rheumatology recommends renal biopsy as essential before initiating treatment as it guides therapy decisions 2, 5
The European League Against Rheumatism suggests that treatment failure should be addressed by switching from MPA to cyclophosphamide or vice versa, adding rituximab, or assessing adherence to treatment and therapeutic drug monitoring 1, 2